Guggenheim Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

A number of other research analysts have also issued reports on the stock. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday. Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Compass Therapeutics currently has a consensus rating of "Buy" and an average price target of $13.38.

Compass Therapeutics Stock Down 9.0 %

CMPX traded down $0.15 on Wednesday, hitting $1.46. 1,726,053 shares of the company traded hands, compared to its average volume of 814,985. The company has a 50 day moving average of $2.76 and a 200-day moving average of $2.10. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market capitalization of $201.89 million, a PE ratio of -3.95 and a beta of 1.19.

Remove Ads

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its position in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $27,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. Finally, Mariner LLC purchased a new position in shares of Compass Therapeutics during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.